Ciofu Oana, Rojo-Molinero Estrella, Macià María D, Oliver Antonio
Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, Costerton Biofilm Center, University of Copenhagen, Copenhagen, Denmark.
Servicio de Microbiología, Hospital Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain.
APMIS. 2017 Apr;125(4):304-319. doi: 10.1111/apm.12673.
Bacterial biofilms are associated with a wide range of infections, from those related to exogenous devices, such as catheters or prosthetic joints, to chronic tissue infections such as those occurring in the lungs of cystic fibrosis patients. Biofilms are recalcitrant to antibiotic treatment due to multiple tolerance mechanisms (phenotypic resistance). This causes persistence of biofilm infections in spite of antibiotic exposure which predisposes to antibiotic resistance development (genetic resistance). Understanding the interplay between phenotypic and genetic resistance mechanisms acting on biofilms, as well as appreciating the diversity of environmental conditions of biofilm infections which influence the effect of antibiotics are required in order to optimize the antibiotic treatment of biofilm infections. Here, we review the current knowledge on phenotypic and genetic resistance in biofilms and describe the potential strategies for the antibiotic treatment of biofilm infections. Of note is the optimization of PK/PD parameters in biofilms, high-dose topical treatments, combined and sequential/alternate therapies or the use antibiotic adjuvants.
细菌生物膜与多种感染相关,从与外部装置(如导管或人工关节)相关的感染到慢性组织感染(如囊性纤维化患者肺部发生的感染)。由于多种耐受机制(表型耐药),生物膜对抗生素治疗具有抗性。这导致尽管暴露于抗生素,生物膜感染仍持续存在,从而易引发抗生素耐药性的产生(基因耐药)。为了优化生物膜感染的抗生素治疗,需要了解作用于生物膜的表型和基因耐药机制之间的相互作用,以及认识到影响抗生素效果的生物膜感染环境条件的多样性。在此,我们综述了关于生物膜中表型和基因耐药的当前知识,并描述了生物膜感染抗生素治疗的潜在策略。值得注意的是生物膜中PK/PD参数的优化、高剂量局部治疗、联合和序贯/交替疗法或使用抗生素佐剂。